Natco Pharma Launches Carboplatin Injection in U.S. to Address Critical Drug Shortage

Key numbers

Market Cap	₹15,400.17 CrPharmaceuticals
P/E Ratio	13.46xSector 45.17x
TTM Revenue	₹3,484.6 CrOperating
RSI	34.56Neutral Zone

Key highlights

• Launch of Carboplatin Injection, a generic equivalent to the reference brand Paraplatin
• Introduced in the U.S. market by subsidiary NATCO Pharma USA LLC
• Manufacturing partnership established with Chennai-based Teyro Labs Pvt Ltd
• Targeted at treating advanced ovarian carcinoma and recurrent disease
• Estimated market size of USD 27.8 million for the 12 months ending June 2026

Strategic Entry into U.S. Oncology Shortage Market

Natco Pharma's launch of Carboplatin Injection comes at a critical time for the U.S. healthcare system, which has been facing supply constraints for essential oncology medications. The product, manufactured in collaboration with Chennai-based Teyro Labs Pvt Ltd, is indicated for the treatment of advanced ovarian carcinoma and palliative care for recurrent disease.

By leveraging its U.S. subsidiary, NATCO Pharma USA LLC, the company is positioning itself to fill a vital gap in the supply chain for generic Paraplatin, which recorded industry sales of approximately USD 27.8 million in the twelve months preceding June 2026.

Product and Market Specifications

• Generic version of Paraplatin indicated for first-line combination therapy in ovarian carcinoma
• Collaborative manufacturing with Teyro Labs Pvt Ltd based in Chennai, India
• Estimated addressable market value of USD 27.8 million based on June 2026 sales data
• Direct response to critical product shortages reported in the U.S. oncology segment
• Part of Natco's strategy to focus on limited competition molecules in the U.S. market

Growth Pipeline and Portfolio Expansion

This launch reinforces Natco's robust generic pipeline, which currently features 28 Para IV assets, including over 20 First-to-File applications. The move follows other significant 2026 milestones, such as the launch of generic Semaglutide in India and Pomalidomide capsules in the United States. While the company reported a year-on-year revenue decline of 44.7% to ₹735.2 crore for the June 2026 quarter, it maintains a healthy operating margin of 25.4%.

The new product entry coincides with the closing of a ₹1,279.36 crore rights issue, intended to support further expansion and facility upgrades.

Operational Footprint and Financial Context

• Current TTM Net Profit stands at ₹1,144.3 crore despite recent revenue headwinds
• Company operates 9 manufacturing sites and 2 R&D facilities across India
• Promoter holding remains stable at 49.39% as of the latest quarterly reporting
• P/E ratio of 13.46x compares to the broader industry average of 45.17x
• Manufacturing facilities carry approvals from US FDA, Brazil ANVISA, and Health Canada

What to watch next

• Closing of the ₹1,279.36 crore rights issue subscription window on October 22, 2026
• Completion of the manufacturing facility upgrade targeted by the end of 2026
• Scheduled agreed generic launch of Carfilzomib in calendar year 2027 following settlement

Natco Pharma · financial snapshot

Share price	₹785.05
Market capitalisation	₹15,400.17 Cr
Revenue (annual)	₹4,078.30 Cr
Net profit (annual)	₹1,418.50 Cr
Revenue (latest quarter)	₹735.20 Cr-0.53% vs previous quarter
Net profit (latest quarter)	₹206.50 Cr-22.92% vs previous quarter
P/E (TTM)	13.46×Sector 45.17×
Promoter holding	49.39%-0.03% QoQ
FII holding	15.99%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.